glioma
Oncology · 2005–2024
5decisions
3medicines
2carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced… | Mar 2024 | Recommended with restriction | 1 individuals |
| dabrafenib and trametinib Treatment of paediatric patients aged ≥12 months to <18 years with BRAF V600E mutation-positive low-grade glioma (LGG) or high-grade glioma (HGG). LGG patients… | Dec 2024 | Recommended with restriction | input received |
| bevacizumab Treatment of relapsed or refractory glioblastoma in patients who have progressed on or are intolerant to temozolomide. | May 2019 | Recommended with restriction | unclear |
| carmustine high grade malignant gliomas, including glioblastoma multiforme and other high-grade gliomas (Grade III and IV) | Mar 2006 | Not recommended | no section in document |
| carmustine Treatment of newly-diagnosed high-grade malignant glioma patients as an adjunct to surgery and radiation. | Nov 2005 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.